Glen Eagle Advisors, LLC Regenxbio Inc. Transaction History
Glen Eagle Advisors, LLC
- $527 Billion
- Q1 2024
A detailed history of Glen Eagle Advisors, LLC transactions in Regenxbio Inc. stock. As of the latest transaction made, Glen Eagle Advisors, LLC holds 150 shares of RGNX stock, worth $2,046. This represents 0.0% of its overall portfolio holdings.
Number of Shares
150Holding current value
$2,046% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RGNX
# of Institutions
192Shares Held
42.6MCall Options Held
80.6KPut Options Held
55.2K-
Black Rock Inc. New York, NY7.6MShares$104 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.88MShares$66.5 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.55MShares$62.1 Million3.78% of portfolio
-
Jpmorgan Chase & CO New York, NY3.72MShares$50.8 Million0.01% of portfolio
-
State Street Corp Boston, MA3.12MShares$42.6 Million0.0% of portfolio
About REGENXBIO Inc.
- Ticker RGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,230,000
- Market Cap $590M
- Description
- REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...